Glenmark gets U.S. FDA approval for Fluticasone Nasal Spray
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Midcap 150 and 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg per spray, which is bioequivalent to Haleon's Flonase Nasal Spray. The product will be distributed in the U.S. by Glenmark Pharmaceuticals Inc. According to IQVIA data for the 12 months ending June 2026, the Flonase market had annual U.S. sales of about $295.2 million. The approval strengthens Glenmark's respiratory portfolio in the U.S.
Positive for the stock. Opens access to a large U.S. market worth about $295 million and strengthens the company's U.S. respiratory franchise.